Overview
A three-peptide healing blend, BPC-157 + TB-500 + KPV, 10 mg each in one vial (30 mg total, equal 1:1:1).
Essentially KLOW without the GHK-Cu, so there’s no copper to manage.
Dosed as one daily SubQ shot that delivers all three at once.
What It Does
BPC-157 and TB-500 drive soft-tissue repair and recovery; KPV adds MC1R/MC3R anti-inflammatory coverage for gut, joints, and skin.
Because they’re in a fixed 1:1:1 ratio, one dose scales all three together.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 10 + 10 + 10 mg | + 2 mL | 5 mg/mL each |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
PROTOCOL, ONCE DAILY, SUBQ
| Phase | Dose (each) | Delivers per shot | Notes |
|---|---|---|---|
| Weeks 1–2, loading | 0.25 mg | 250 mcg BPC / TB / KPV | Ease in; watch injection-site tolerance. |
| Week 3 onward, working | 0.50 mg | 500 mcg BPC / TB / KPV | Standard working dose for all three. 10 units/day lands each peptide on its standard working dose at once, BPC-157 500 mcg, TB-500’s 500 mcg/day “rides-along” daily cadence, KPV low-systemic 500 mcg. Inject near the target tissue (abdomen for gut/systemic); rotate sites. Daily dosing is required, BPC-157’s half-life is short. |
UNIT MAP (@ 5 MG/ML) CYCLE & SUPPLY
| Draw | Volume | Each peptide | 6–8 weeks on / 2–4 weeks off. No GHK-Cu → no copper washout (more |
|---|---|---|---|
| 5u | 0.05 mL | 250 mcg | forgiving than GLOW/KLOW). One vial ≈ 20 days at 10u/day. Store reconstituted 36–46°F, out of light. |
| 10u | 0.10 mL | 500 mcg | |
| 15u | 0.15 mL | 750 mcg By sex: Unisex (BPC-157 + TB-500 + KPV repair), same protocol for men and women, no cycle effect. Avoid in pregnancy. |
Handling & Stacking
Safety & Patient Education
- Active or suspected malignancy.
- TB-500 is angiogenic systemically; BPC-157 drives angiogenesis locally via VEGF; KPV carries no growth signal and there’s no copper here.
- Theoretical, but neither can tell healthy tissue from a tumour you don’t know about.
- Screen age-appropriately before a long run; stop for any new lump.
- Active bleeding, recent surgery, or anticoagulant/antiplatelet therapy (TB-500 vascular effects) Alpha-MSH / melanocortin allergy (KPV component) Pregnancy and lactation Hypersensitivity to any of the three peptides
- Daily dosing is required, BPC-157's half-life is short.
- Inject near the target tissue, or abdomen for systemic effect; rotate sites.
- Keep the blend at ~10u and add standalone KPV for heavier gut coverage rather than over-running the blend (which drags TB-500 high).
- None FDA-approved, all three were RECOMMENDED for the 503A bulks list by PCAC (Jul 2026; advisory, non-binding); no human RCT on this combination.
- Request a COA.
